Ticker

SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California on April 19, 2026. The Company demonstrated new data on its approach of simultaneously activating…

SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today reported its fourth quarter and full-year 2025 operating and financial results and reviewed recent business highlights.

SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented on its proprietary manufacturing process for CLD-401, the Company's first lead candidate from its RedTail platform, at the BioProcessing Summit in Barcelona.

$12 Million of Tranche Warrants Potential Financing Within One Year From Closing $12 Million of Tranche Warrants Potential Financing Within One Year From Closing

Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of Closing